Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 103

Sort by

Sort Order Select

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

Blood (2025) 146 (Supplement 1): 226.

https://doi.org/10.1182/blood-2025-226

Published: 2025

Journal Articles

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

Blood (2025) 146 (Supplement 1): 2137.

https://doi.org/10.1182/blood-2025-2137

Published: 2025

Journal Articles

Dissecting the heterogeneity of IGHV-mutated CLL: An eric study.

Thomas Chatzikonstantinou, Andreas Agathangelidis, Persefoni Talimtzi, Stamatia Laidou, Eva Minga, Athanasios Roussos, Maria Angelopoulou, Miguel Arguello De Tomas, Darko Antic, Fanny Baran-Marszak, Csaba Bödör, Francesc Bosch Albareda, Mark Catherwood, Sophia Chatzileontiadou, Caterina Chessa, Marta Coscia, Marta Crespo, Antonio Cuneo, Zadie Davis, Maria Dimou, Michael Doubek, Maria Efstathopoulou, Blanca Espinet, Gianluca Gaidano, Ritu Gupta, Eleftheria Hatzimichael, Yair Herishanu, Thalia Karamanli, Eliana Konstantinou, Ioannis Kotsianidis, Andreas Epameinondas Koumpis, Tamas Laszlo, Vincent Levy, Alexandros Machairas, Francesca Martini, Riccardo Moia, Samir Mouhssine, Ana Muntanola Prat, Roberta Murru, Eugenia Mpalaoura, Gerassimos Pangalis, Maria Papaioannou, Sarka Pavlova, Karla Plevova, Sarka Pospisilova, Anna Puiggros, Lata Rani, Gian Matteo Rigolin, Ilaria Romano, Davide Rossi, Angel Serna, Martin Simkovic, Lukas Smolej, Niki Stavrogianni, Kristina Tomic Vujovic, Livio Trentin, Theodoros Vassilakopoulos, Andrea Visentin, Candida Vitale, George Vrachiolias, Lydia Scarfo, Anastasia Chatzidimitriou, Paolo Ghia, Kostas Stamatopoulos

Blood (2025) 146 (Supplement 1): 2120.

https://doi.org/10.1182/blood-2025-2120

Published: 2025

Journal Articles

Treatment with acalabrutinib in IGHV mutated setting and presence of splenomegaly are the main predictors of faster lymphocyte count decrease in CLL during monotherapy with cbtki

Blood (2025) 146 (Supplement 1): 7427.

https://doi.org/10.1182/blood-2025-7427

Published: 2025

Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study

Blood (2025) 146 (Supplement 1): 85.

https://doi.org/10.1182/blood-2025-85

Published: 2025

Journal Articles

Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial

Othman Al-Sawaf, Janina Stumpf, Can Zhang, Florian Simon, Francesc Bosch Albareda, Emadoldin Feyzi, Paolo Ghia, Michael Gregor, Arnon Kater, Vesa Lindström, Mattias Mattsson, Carsten Niemann, Philipp Staber, Tamar Tadmor, Patrick Thornton, Clemens-Martin Wendtner, Ann Janssens, Thomas Noesslinger, Jan-Paul Bohn, Caspar da Cunha-Bang, Christian Poulsen, Juha Ranti, Thomas Illmer, Bjoern Schoettker, Sebastian Böttcher, Tobias Gaska, Elisabeth Vandenberghe, Ruth Clifford, Ohad Benjamini, Annamaria Frustaci, Lydia Scarfo, Paolo Sportoletti, John Schreurs, Mark-David Levin, Hanneke van der Straaten, Marjolein van der Klift, Hoa Tran, Javier de la Serna, Javier Loscertales, Oscar Lindblad, Anna Bergendahl Sandstedt, Jeroen Goede, Michael Baumann, Anna Maria Fink, Kirsten Fischer, Matthias Ritgen, Karl-Anton Kreuzer, Christof Schneider, Eugen Tausch, Stephan Stilgenbauer, Sandra Robrecht, Barbara Eichhorst, Michael Hallek

Blood (2025) 146 (Supplement 1): 1.

https://doi.org/10.1182/blood-2025-1

Published: 2025

Journal Articles

Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study

Andrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfo, Persefoni Talimtzi, Maria Angelopoulou, Tomas Arpas, Laura Ballotta, Leonidas Benetatos, Ana Margarida Bertolo, Horia Bumbea, Maurizio Cavallari, Anastasia Chatzidimitriou, Dominik Chraniuk, Anna Christoforidou, Francesca Cibien, Antonio Cuneo, Maria Ilaria del Principe, Marina Deodato, Enrico Derenzini, Michael Doubek, Fabiana Esposito, Lucia Farina, Gianmarco Favrin, Isacco Ferrarini, Annamaria Frustaci, Andrea Galitzia, Massimo Gentile, Iulia Roxana Iancu, Vanessa Innao, krzysztof jamroziak, Elzbieta Kalicinska, Maria Kislova, Ioannis Kyriakou, Luca Laurenti, Enrico Lista, Javier Loscertales, Alexandros Machairas, Giorgia Marcato, Francesca Martini, Nilla Maschio, Eva Minga, Riccardo Moia, Roberta Murru, Maura Nicolosi, Jacopo Olivieri, Carolina Pavlovsky, Miguel Pavlovsky, Sara Pepe, Ernesto Perez Persona, Giuseppe Petruzzellis, Gian Matteo Rigolin, Alessandro Sanna, Marina Siakantaris, Paolo Sportoletti, Oana Stanca, Niki Stavrogianni, Tamar Tadmor, Annamaria Tomasso, Marzia Varettoni, Theodoros Vassilakopoulos, Eva Gimeno Vazquez, Candida Vitale, Mohamed Yassin, Mihnea Zdrenghea, Klaudia Zielonka, Livio Trentin, Kostas Stamatopoulos, Paolo Ghia

Blood (2025) 146 (Supplement 1): 6287.

https://doi.org/10.1182/blood-2025-6287

Published: 2025

Journal Articles

Real-world treatment patterns and outcomes in patients with CLL and cardiovascular comorbidities: Interim analysis of the multicenter study conducted by eric.

Thomas Chatzikonstantinou, Sevasti Konstantinou, Persefoni Talimtzi, Eva Minga, Maria Angelopoulou, Francesco Angotzi, Marcello Bradaschia, Sophia Chatzileontiadou, Caterina Chessa, Marta Crespo, Maria Dimou, Alessandro Gozzetti, Ritu Gupta, Eliana Konstantinou, Andreas Epameinondas Koumpis, Alexandros Machairas, Francesca Martini, Riccardo Moia, Samir Mouhssine, Roberta Murru, Leila Perobelli, Lata Rani, Ilaria Romano, Gian Matteo Rigolin, Angel Serna, Andrea Visentin, Candida Vitale, George Vrachiolias, Celso Arrais-Rodrigues, Rodrigo Santucci da Silva, Carlos Chiattone, Francesc Bosch Albareda, Anastasia Chatzidimitriou, Marta Coscia, Antonio Cuneo, Gianluca Gaidano, Eleftheria Hatzimichael, Yair Herishanu, Ioannis Kotsianidis, Panagiotis Panagiotidis, Maria Papaioannou, Davide Rossi, Niki Stavrogianni, Livio Trentin, Theodoros Vassilakopoulos, Kostas Stamatopoulos, Paolo Ghia, Lydia Scarfo

Blood (2025) 146 (Supplement 1): 5665.

https://doi.org/10.1182/blood-2025-5665

Published: 2025

Journal Articles

Survival differences of patients with treatment-naive CLL between the chemoimmunotherapy and BTKi eras: An eric study.

Thomas Chatzikonstantinou, Persefoni Talimtzi, Eva Minga, Maria Angelopoulou, Miguel Arguello De Tomas, Darko Antic, Celso Arrais-Rodrigues, Francesc Bosch Albareda, Marcello Bradaschia, Alessandro Cellini, Mark Catherwood, Sophia Chatzileontiadou, Caterina Chessa, Carlos Chiattone, Rosa Collado, Marta Coscia, Marta Crespo, Antonio Cuneo, Zadie Davis, Maria Dimou, Michael Doubek, Maria Efstathopoulou, Blanca Espinet, Gianluca Gaidano, Rocio Garcia-Serra, Alessandro Gozzetti, Ritu Gupta, Eleftheria Hatzimichael, Yair Herishanu, Ozren Jaksic, Maria Kislova, Eliana Konstantinou, Sevasti Konstantinou, Maya Koren Michowitz, Ioannis Kotsianidis, Andreas Epameinondas Koumpis, Luca Laurenti, Alexandros Machairas, Francesca Martini, Riccardo Moia, Samir Mouhssine, Ana Muntanola Prat, Roberta Murru, Rocio Nieves Salgado Sanchez, Gerassimos Pangalis, Maria Papaioannou, Sarka Pavlova, Leila Perobelli, Sarka Pospisilova, Anna Puiggros, Claus Rainer, Sergio Ramos, Lata Rani, Gian Matteo Rigolin, Ilaria Romano, Davide Rossi, Rodrigo Santucci, Angel Serna, Marina Siakantaris, Talita Silveira, Paolo Sportoletti, Niki Stavrogianni, Annamaria Tomasso, Kristina Tomic Vujovic, Livio Trentin, Theodoros Vassilakopoulos, Andrea Visentin, Candida Vitale, George Vrachiolias, Munci Yagci, Seyma Yildiz, Anastasia Chatzidimitriou, Kostas Stamatopoulos, Paolo Ghia, Lydia Scarfo

Blood (2025) 146 (Supplement 1): 5664.

https://doi.org/10.1182/blood-2025-5664

Published: 2025

Journal Articles

Integrated multi-omic profiling reveals two biologically distinct subgroups of splenic marginal zone lymphoma with prognostic relevance

Blood (2025) 146 (Supplement 1): 353.

https://doi.org/10.1182/blood-2025-353

Published: 2025

Journal Articles

Severe COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia or Indolent B-Cell Non-Hodgkin Lymphoma Who Received Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab in Italy: Preliminary Results of the Observational Study By the Gimema Working Party on Chronic Lymphoproliferative Disorders and By the Fondazione Italiana Linfomi

Blood (2024) 144 (Supplement 1): 1872.

https://doi.org/10.1182/blood-2024-199014

Published: 2024

Journal Articles

Acalabrutinib in High-Risk Chronic Lymphocytic Leukemia Patients Naïve or Previous Treated. a Multicenter Retrospective Observational Real-Life Experience

Blood (2024) 144 (Supplement 1): 6798.

https://doi.org/10.1182/blood-2024-203557

Published: 2024

Journal Articles

Improving Quality of Life Based on Electronic Patient Reported Outcomes in Patients with CLL and MDS: The Mypal Study

Blood (2024) 144 (Supplement 1): 2358.

https://doi.org/10.1182/blood-2024-204788

Published: 2024

Journal Articles

Prevalence and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Chronic Lymphocytic Leukemia and Richter Transformation

Blood (2024) 144 (Supplement 1): 762.

https://doi.org/10.1182/blood-2024-194469

Published: 2024

Journal Articles

Baseline Characteristics from Arise Study, an Italian Non-Interventional Study Assessing the Real-World Use of Acalabrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2024) 144 (Supplement 1): 7747.

https://doi.org/10.1182/blood-2024-199041

Published: 2024

Journal Articles

Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study

T C, Eva Minga, Georgios Karakatsoulis, Elisa Albi, Miguel Alcoceba, David Allsup, Francesca Bacchiarri, Sotiria Besikli-Dimou, Sofia Chatzileontiadou, Rosa Collado, Zadie Davis, Maria Dimou, David Donaldson, Maria Efstathopoulou, Sara Galimberti, Andrea Galitzia, Eva Gimeno, Valerio Guarente, Eleftheria Hatzimichael, Jose-Angel Hernandez-Rivas, Gloria Iacoboni, Iliana Konstantinou, Ioannis Kotsianidis, Jana Kotaskova, Andreas Epameinondas Koumpis, Zuzana Kubova, Jorge Labrador, Luca Laurenti, Juan Marquet, Stanislava Maslejova, Carlota Mayor-Bastida, Fatima Miras, Riccardo Moia, Almudena Navarro-Bailon, Jacopo Olivieri, Maria Papaioannou, Anna Puiggros, Gian Matteo Rigolin, Mattia Schipani, Tereza Shokralla, Martin Simkovic, Antigoni Tranidou, Theodoros Vassilakopoulos, Andrea Visentin, Candida Vitale, George Vrachiolias, Renata Walewska, Lucrecia Yanez San Segundo, Jana Zuchnicka, David Graham Oscier, Alessandro Gozzetti, Panayiotis Panayiotidis, Francesc Bosch, Paolo Sportoletti, Blanca Espinet, Gerassimos Pangalis, Maria Angelopoulou, Tomas Papajik, Roberta Murru, Marta Coscia, Antonio Cuneo, Gianluca Gaidano, Niki Stavrogianni, Livio Trentin, Lukas Smolej, Mark Caterwood, Martin Spacek, Sarka Pospisilova, Michael Doubek, Anastasia Chatzidimitriou, Kostas Stamatopoulos, Paolo Ghia, Lydia Scarfo

Blood (2024) 144 (Supplement 1): 4619.

https://doi.org/10.1182/blood-2024-202046

Published: 2024

Journal Articles

Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway

Blood (2024) 144 (Supplement 1): 73.

https://doi.org/10.1182/blood-2024-205557

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study

Meghan C. Thompson, Ricardo D. Parrondo, Anna Maria Frustaci, John N. Allan, Paolo Ghia, Irina Mocanu, Constantine S. Tam, Judith Trotman, Inhye E. Ahn, Stephan Stilgenbauer, Lydia Scarfo, Xiangmei Chen, Kunthel By, Shannon Fabre, Daniel O. Persky, Amit Agarwal, John F. Seymour

Blood (2024) 144 (Supplement 1): 885.

https://doi.org/10.1182/blood-2024-199116

Published: 2024

Journal Articles

CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 4504.

https://doi.org/10.1182/blood-2024-200050

Published: 2024

Journal Articles

Evidence of Defective Cell-Autonomous Signalling By B Cell Receptors in CLL Stereotyped Subset #1

Claudia Minici, Paolo G. Cocomazzi, Can Akpınaroğlu, Anastasia Iatrou, Maria Gounari, Michela Frenquelli, Lydia Scarfo, Christian Buske, Andreas Agathangelidis, Hassan Jumaa, Palash Maity, Paolo Ghia, Kostas Stamatopoulos, Massimo Degano

Blood (2023) 142 (Supplement 1): 3255.

https://doi.org/10.1182/blood-2023-181702

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

Dissecting the heterogeneity of IGHV-mutated CLL: An eric study.

Treatment with acalabrutinib in IGHV mutated setting and presence of splenomegaly are the main predictors of faster lymphocyte count decrease in CLL during monotherapy with cbtki

Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study

Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial

Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study

Real-world treatment patterns and outcomes in patients with CLL and cardiovascular comorbidities: Interim analysis of the multicenter study conducted by eric.

Survival differences of patients with treatment-naive CLL between the chemoimmunotherapy and BTKi eras: An eric study.

Integrated multi-omic profiling reveals two biologically distinct subgroups of splenic marginal zone lymphoma with prognostic relevance

Acalabrutinib in High-Risk Chronic Lymphocytic Leukemia Patients Naïve or Previous Treated. a Multicenter Retrospective Observational Real-Life Experience

Improving Quality of Life Based on Electronic Patient Reported Outcomes in Patients with CLL and MDS: The Mypal Study

Prevalence and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Chronic Lymphocytic Leukemia and Richter Transformation

Baseline Characteristics from Arise Study, an Italian Non-Interventional Study Assessing the Real-World Use of Acalabrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study

Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study

CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

Evidence of Defective Cell-Autonomous Signalling By B Cell Receptors in CLL Stereotyped Subset #1

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only